Hepatitis B core–based virus–like particles to present heterologous epitopes

References

• Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol. Rev. 28, 112–125 (2006).
   PubMed Web of Science ®Google Scholar
• Rivers TM. Viruses and Koch’s Postulates. J. Bacteriol. 33(1), 1–12 (1937).
   PubMedGoogle Scholar
• Blumberg BS, Alter HJ, Visnich S. A ‘new’ antigen in leukemia sera. JAMA 191, 541–546 (1965).
   PubMed Web of Science ®Google Scholar
• Blumberg BS, Sutnick AI, London WT. Hepatitis and leukemia: their relation to Australia antigen. Bull. N. Y. Acad. Med. 44(12), 1566–1586 (1968).
   PubMedGoogle Scholar
• Prince AM. An antigen detected in the blood during the incubation period of serum hepatitis. Proc. Natl Acad. Sci. USA 60(3), 814–821 (1968).
   PubMed Web of Science ®Google Scholar
• Wang GH, Seeger C. The reverse transcriptase of hepatitis B virus acts as a protein primer for viral DNA synthesis. Cell 71(4), 663–670 (1992).
   PubMed Web of Science ®Google Scholar
• Weber M, Bronsema V, Bartos H, Bosserhoff A, Bartenschlager R, Schaller H. Hepadnavirus P protein utilizes a tyrosine residue in the TP domain to prime reverse transcription. J. Virol. 68(5), 2994–2999 (1994).
   PubMedGoogle Scholar
• Szmuness W, Stevens CE, Harley EJ et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N. Engl. J. Med. 303(15), 833–841 (1980).
   PubMed Web of Science ®Google Scholar
• Jilg W, Lorbeer B, Schmidt M, Wilske B, Zoulek G, Deinhardt F. Clinical evaluation of a recombinant hepatitis B vaccine. Lancet 2(8413), 1174–1175 (1984).
   PubMed Web of Science ®Google Scholar
• McAleer WJ, Buynak EB, Maigetter RZ, Wampler DE, Miller WJ, Hilleman MR. Human hepatitis B vaccine from recombinant yeast. Nature 307(5947), 178–180 (1984).
   PubMed Web of Science ®Google Scholar
• Mangold CM, Streeck RE. Mutational analysis of the cysteine residues in the hepatitis B virus small envelope protein. J. Virol. 67(8), 4588–4597 (1993).
   PubMed Web of Science ®Google Scholar
• Heermann KH, Kruse F, Seifer M, Gerlich WH. Immunogenicity of the gene S and Pre-S domains in hepatitis B virions and HBsAg filaments. Intervirology 28(1), 14–25 (1987).
   PubMedGoogle Scholar
• Neurath AR, Kent SB, Strick N, Parker K. Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus. Cell 46(3), 429–436 (1986).
   PubMed Web of Science ®Google Scholar
• Schulze A, Schieck A, Ni Y, Mier W, Urban S. Fine mapping of pre-S sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction. J. Virol. 84(4), 1989–2000 (2010).
   PubMed Web of Science ®Google Scholar
• Ferrari C, Penna A, Bertoletti A et al. The preS1 antigen of hepatitis B virus is highly immunogenic at the T cell level in man. J. Clin. Invest. 84(4), 1314–1319 (1989).
   PubMedGoogle Scholar
• Milich DR. T- and B-cell recognition of hepatitis B viral antigens. Immunol. Today 9(12), 380–386 (1988).
   PubMedGoogle Scholar
• Pillot J, Poynard T, Elias A et al. Weak immunogenicity of the pre-S2 sequence and lack of circumventing effect on the unresponsiveness to the hepatitis B virus vaccine. Vaccine 13(3), 289–294 (1995).
   PubMedGoogle Scholar
• Shapira MY, Zeira E, Adler R, Shouval D. Rapid seroprotection against hepatitis B following the first dose of a Pre-S1/Pre-S2/S vaccine. J. Hepatol. 34(1), 123–127 (2001).
   PubMed Web of Science ®Google Scholar
• Zuckerman JN, Zuckerman AJ, Symington I et al.; UK Hepacare Study Group. Evaluation of a new hepatitis B triple-antigen vaccine in inadequate responders to current vaccines. Hepatology 34(4 Pt 1), 798–802 (2001).
   PubMedGoogle Scholar
• Rendi-Wagner P, Shouval D, Genton B et al. Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine. Vaccine 24(15), 2781–2789 (2006).
   PubMed Web of Science ®Google Scholar
• Sylvan SP, Madalinski K, Hellström UB. Anti-preS responses influence the anti-HBs response in newborns after vaccination with the third generation Sci-B-Vac vaccine. Vaccine 28(2), 446–451 (2009).
   PubMedGoogle Scholar
• Bruss V, Vieluf K. Functions of the internal pre-S domain of the large surface protein in hepatitis B virus particle morphogenesis. J. Virol. 69(11), 6652–6657 (1995).
   PubMed Web of Science ®Google Scholar
• Zhou S, Standring DN. Hepatitis B virus capsid particles are assembled from core-protein dimer precursors. Proc. Natl Acad. Sci. USA 89(21), 10046–10050 (1992).
   PubMedGoogle Scholar
• Crowther RA, Kiselev NA, Böttcher B et al. Three-dimensional structure of hepatitis B virus core particles determined by electron cryomicroscopy. Cell 77(6), 943–950 (1994).
   PubMedGoogle Scholar
• Dryden KA, Wieland SF, Whitten-Bauer C, Gerin JL, Chisari FV, Yeager M. Native hepatitis B virions and capsids visualized by electron cryomicroscopy. Mol. Cell 22(6), 843–850 (2006).
   PubMed Web of Science ®Google Scholar
• Messageot F, Salhi S, Eon P, Rossignol JM. Proteolytic processing of the hepatitis B virus e antigen precursor. J. Biol. Chem. 278(2), 891 (2003).
   PubMed Web of Science ®Google Scholar
• Schödel F, Peterson D, Zheng J, Jones JE, Hughes JL, Milich DR. Structure of hepatitis B virus core and e-antigen. A single precore amino acid prevents nucleocapsid assembly. J. Biol. Chem. 268(2), 1332–1337 (1993).
   PubMed Web of Science ®Google Scholar
• Milich DR, Jones JE, Hughes JL, Price J, Raney AK, McLachlan A. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proc. Natl Acad. Sci. USA 87(17), 6599–6603 (1990).
   PubMed Web of Science ®Google Scholar
• Walsh R, Locarnini S. Hepatitis B precore protein: pathogenic potential and therapeutic promise. Yonsei Med. J. 53(5), 875–885 (2012).
   PubMedGoogle Scholar
• Porterfield JZ, Dhason MS, Loeb DD, Nassal M, Stray SJ, Zlotnick A. Full-length hepatitis B virus core protein packages viral and heterologous RNA with similarly high levels of cooperativity. J. Virol. 84(14), 7174–7184 (2010).
   PubMed Web of Science ®Google Scholar
• Watts NR, Conway JF, Cheng N et al. The morphogenic linker peptide of HBV capsid protein forms a mobile array on the interior surface. EMBO J. 21(5), 876–884 (2002).
   PubMed Web of Science ®Google Scholar
• Zlotnick A, Cheng N, Conway JF et al. Dimorphism of hepatitis B virus capsids is strongly influenced by the C-terminus of the capsid protein. Biochemistry 35(23), 7412–7421 (1996).
   PubMed Web of Science ®Google Scholar
• Wynne SA, Crowther RA, Leslie AG. The crystal structure of the human hepatitis B virus capsid. Mol. Cell 3(6), 771–780 (1999).
   PubMed Web of Science ®Google Scholar
• Barker LF, Murray R. Relationship of virus dose to incubation time of clinical hepatitis and time of appearance of hepatitis–associated antigen. Am. J. Med. Sci. 263(1), 27–33 (1972).
   PubMed Web of Science ®Google Scholar
• Bartenschlager R, Schaller H. Hepadnaviral assembly is initiated by polymerase binding to the encapsidation signal in the viral RNA genome. EMBO J. 11(9), 3413–3420 (1992).
   PubMed Web of Science ®Google Scholar
• Hirsch RC, Lavine JE, Chang LJ, Varmus HE, Ganem D. Polymerase gene products of hepatitis B viruses are required for genomic RNA packaging as wel as for reverse transcription. Nature 344(6266), 552–555 (1990).
   PubMed Web of Science ®Google Scholar
• Beck J, Nassal M. Efficient Hsp90-independent in vitro activation by Hsc70 and Hsp40 of duck hepatitis B virus reverse transcriptase, an assumed Hsp90 client protein. J. Biol. Chem. 278(38), 36128–36138 (2003).
   PubMedGoogle Scholar
• Hu J, Flores D, Toft D, Wang X, Nguyen D. Requirement of heat shock protein 90 for human hepatitis B virus reverse transcriptase function. J. Virol. 78(23), 13122–13131 (2004).
   PubMed Web of Science ®Google Scholar
• Wang X, Grammatikakis N, Hu J. Role of p50/CDC37 in hepadnavirus assembly and replication. J. Biol. Chem. 277(27), 24361–24367 (2002).
   PubMedGoogle Scholar
• Daub H, Blencke S, Habenberger P et al. Identification of SRPK1 and SRPK2 as the major cellular protein kinases phosphorylating hepatitis B virus core protein. J. Virol. 76(16), 8124–8137 (2002).
   PubMedGoogle Scholar
• Kann M, Gerlich WH. Effect of core protein phosphorylation by protein kinase C on encapsidation of RNA within core particles of hepatitis B virus. J. Virol. 68(12), 7993–8000 (1994).
   PubMed Web of Science ®Google Scholar
• Kau JH, Ting LP. Phosphorylation of the core protein of hepatitis B virus by a 46-kilodalton serine kinase. J. Virol. 72(5), 3796–3803 (1998).
   PubMedGoogle Scholar
• Roseman AM, Berriman JA, Wynne SA, Butler PJ, Crowther RA. A structural model for maturation of the hepatitis B virus core. Proc. Natl Acad. Sci. USA 102(44), 15821–15826 (2005).
   PubMedGoogle Scholar
• Böttcher B, Wynne SA, Crowther RA. Determination of the fold of the core protein of hepatitis B virus by electron cryomicroscopy. Nature 386(6620), 88–91 (1997).
   PubMed Web of Science ®Google Scholar
• Burrell CJ, Mackay P, Greenaway PJ, Hofschneider PH, Murray K. Expression in Escherichia coli of hepatitis B virus DNA sequences cloned in plasmid pBR322. Nature 279(5708), 43–47 (1979).
   PubMedGoogle Scholar
• Hardy K, Stahl S, Küpper H. Production in B. subtilis of hepatitis B core antigen and a major antigen of foot and mouth disease virus. Nature 293(5832), 481–483 (1981).
   PubMed Web of Science ®Google Scholar
• Schödel F, Milich DR, Will H. Hepatitis B virus nucleocapsid/pre-S2 fusion proteins expressed in attenuated Salmonella for oral vaccination. J. Immunol. 145(12), 4317–4321 (1990).
   PubMed Web of Science ®Google Scholar
• Kniskern PJ, Hagopian A, Montgomery DL et al. Unusually high-level expression of a foreign gene (hepatitis B virus core antigen) in Saccharomyces cerevisiae. Gene 46(1), 135–141 (1986).
   PubMedGoogle Scholar
• Plüddemann A, Van Zyl WH. Evaluation of Aspergillus niger as host for virus-like particle production, using the hepatitis B surface antigen as a model. Curr. Genet. 43(6), 439–446 (2003).
   PubMedGoogle Scholar
• Rolland D, Gauthier M, Dugua JM et al. Purification of recombinant HBc antigen expressed in Escherichia coli and Pichia pastoris: comparison of size-exclusion chromatography and ultracentrifugation. J. Chromatogr. B Biomed. Sci. Appl. 753(1), 51–65 (2001).
   PubMedGoogle Scholar
• Hirschman SZ, Price P, Garfinkel E, Christman J, Acs G. Expression of cloned hepatitis B virus DNA in human cell cultures. Proc. Natl Acad. Sci. USA 77(9), 5507–5511 (1980).
   PubMedGoogle Scholar
• Standring DN, Ou JH, Masiarz FR, Rutter WJ. A signal peptide encoded within the precore region of hepatitis B virus directs the secretion of a heterogeneous population of e antigens in Xenopus oocytes. Proc. Natl Acad. Sci. USA 85(22), 8405–8409 (1988).
   PubMed Web of Science ®Google Scholar
• Takehara K, Ireland D, Bishop DH. Co-expression of the hepatitis B surface and core antigens using baculovirus multiple expression vectors. J. Gen. Virol. 69 (Pt 11), 2763–2777 (1988).
   PubMedGoogle Scholar
• Tsuda S, Yoshioka K, Tanaka T et al. Application of the human hepatitis B virus core antigen from transgenic tobacco plants for serological diagnosis. Vox Sang. 74(3), 148–155 (1998).
   PubMedGoogle Scholar
• Bruss V, Ganem D. The role of envelope proteins in hepatitis B virus assembly. Proc. Natl Acad. Sci. USA 88(3), 1059–1063 (1991).
   PubMedGoogle Scholar
• Ueda K, Tsurimoto T, Matsubara K. Three envelope proteins of hepatitis B virus: large S, middle S, and major S proteins needed for the formation of Dane particles. J. Virol. 65(7), 3521–3529 (1991).
   PubMedGoogle Scholar
• Clarke BE, Newton SE, Carroll AR et al. Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein. Nature 330(6146), 381–384 (1987).
   PubMed Web of Science ®Google Scholar
• Cohen BJ, Richmond JE. Electron microscopy of hepatitis B core antigen synthesized in E. coli. Nature 296(5858), 677–679 (1982).
   PubMed Web of Science ®Google Scholar
• Cohen BJ, Cossart YE. Application of a screening test for antibody the hepatitis B core antigen. J. Clin. Pathol. 30(8), 709–713 (1977).
   PubMedGoogle Scholar
• Winther MD, Allen G, Bomford RH, Brown F. Bacterially expressed antigenic peptide from foot-and-mouth disease virus capsid elicits variable immunologic responses in animals. J. Immunol. 136(5), 1835–1840 (1986).
   PubMedGoogle Scholar
• Conway JF, Cheng N, Zlotnick A, Wingfield PT, Stahl SJ, Steven AC. Visualization of a 4-helix bundle in the hepatitis B virus capsid by cryo-electron microscopy. Nature 386(6620), 91–94 (1997).
   PubMed Web of Science ®Google Scholar
• Salfeld J, Pfaff E, Noah M, Schaller H. Antigenic determinants and functional domains in core antigen and e antigen from hepatitis B virus. J. Virol. 63(2), 798–808 (1989).
   PubMed Web of Science ®Google Scholar
• Gallina A, Bonelli F, Zentilin L, Rindi G, Muttini M, Milanesi G. A recombinant hepatitis B core antigen polypeptide with the protamine-like domain deleted self-assembles into capsid particles but fails to bind nucleic acids. J. Virol. 63(11), 4645–4652 (1989).
   PubMed Web of Science ®Google Scholar
• De Filette M, Min Jou W, Birkett A et al. Universal influenza A vaccine: optimization of M2-based constructs. Virology 337(1), 149–161 (2005).
   PubMed Web of Science ®Google Scholar
• Schödel F, Moriarty AM, Peterson DL et al. The position of heterologous epitopes inserted in hepatitis B virus core particles determines their immunogenicity. J. Virol. 66(1), 106–114 (1992).
   PubMed Web of Science ®Google Scholar
• Nassal M, Skamel C, Vogel M et al. Development of hepatitis B virus capsids into a whole-chain protein antigen display platform: new particulate Lyme disease vaccines. Int. J. Med. Microbiol. 298(1–2), 135–142 (2008).
   PubMedGoogle Scholar
• Kratz PA, Böttcher B, Nassal M. Native display of complete foreign protein domains on the surface of hepatitis B virus capsids. Proc. Natl Acad. Sci. USA 96(5), 1915–1920 (1999).
   PubMed Web of Science ®Google Scholar
• Skamel C, Ploss M, Böttcher B et al. Hepatitis B virus capsid-like particles can display the complete, dimeric outer surface protein C and stimulate production of protective antibody responses against Borrelia burgdorferi infection. J. Biol. Chem. 281(25), 17474–17481 (2006).
   PubMed Web of Science ®Google Scholar
• Nassal M, Skamel C, Kratz PA, Wallich R, Stehle T, Simon MM. A fusion product of the complete Borrelia burgdorferi outer surface protein A (OspA) and the hepatitis B virus capsid protein is highly immunogenic and induces protective immunity similar to that seen with an effective lipidated OspA vaccine formula. Eur. J. Immunol. 35(2), 655–665 (2005).
   PubMed Web of Science ®Google Scholar
• Walker A, Skamel C, Vorreiter J, Nassal M. Internal core protein cleavage leaves the hepatitis B virus capsid intact and enhances its capacity for surface display of heterologous whole chain proteins. J. Biol. Chem. 283(48), 33508–33515 (2008).
   PubMed Web of Science ®Google Scholar
• Jegerlehner A, Tissot A, Lechner F et al. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine 20(25–26), 3104–3112 (2002).
   PubMed Web of Science ®Google Scholar
• Wang XJ, Gu K, Xiong QY et al. A novel virus-like particle based on hepatitis B core antigen and substrate-binding domain of bacterial molecular chaperone DnaK. Vaccine 27(52), 7377–7384 (2009).
   PubMedGoogle Scholar
• Schwarz K, Meijerink E, Speiser DE et al. Efficient homologous prime-boost strategies for T cell vaccination based on virus-like particles. Eur. J. Immunol. 35(3), 816–821 (2005).
   PubMed Web of Science ®Google Scholar
• Milich DR, McLachlan A. The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen. Science 234(4782), 1398–1401 (1986).
   PubMed Web of Science ®Google Scholar
• Milich DR, McLachlan A, Moriarty A, Thornton GB. Immune response to hepatitis B virus core antigen (HBcAg): localization of T cell recognition sites within HBcAg/HBeAg. J. Immunol. 139(4), 1223–1231 (1987).
   PubMed Web of Science ®Google Scholar
• Ferrari C, Penna A, Bertoletti A, Fiaccadori F. Cell mediated immune response to hepatitis B virus nucleocapsid antigen. Arch. Virol. Suppl. 8, 91–101 (1993).
   PubMedGoogle Scholar
• Milich DR, Peterson DL, Schödel F, Jones JE, Hughes JL. Preferential recognition of hepatitis B nucleocapsid antigens by Th1 or Th2 cells is epitope and major histocompatibility complex dependent. J. Virol. 69(5), 2776–2785 (1995).
   PubMedGoogle Scholar
• Milich DR, McLachlan A, Thornton GB, Hughes JL. Antibody production to the nucleocapsid and envelope of the hepatitis B virus primed by a single synthetic T cell site. Nature 329(6139), 547–549 (1987).
   PubMed Web of Science ®Google Scholar
• Milich DR, Chen M, Schödel F, Peterson DL, Jones JE, Hughes JL. Role of B cells in antigen presentation of the hepatitis B core. Proc. Natl Acad. Sci. USA 94(26), 14648–14653 (1997).
   PubMed Web of Science ®Google Scholar
• Lee BO, Tucker A, Frelin L et al. Interaction of the hepatitis B core antigen and the innate immune system. J. Immunol. 182(11), 6670–6681 (2009).
   PubMed Web of Science ®Google Scholar
• Zhang Y, Song S, Liu C et al. Generation of chimeric HBc proteins with epitopes in E. coli: formation of virus-like particles and a potent inducer of antigen-specific cytotoxic immune response and anti-tumor effect in vivo. Cell. Immunol. 247(1), 18–27 (2007).
   PubMed Web of Science ®Google Scholar
• Ding FX, Wang F, Lu YM et al. Multiepitope peptide-loaded virus-like particles as a vaccine against hepatitis B virus-related hepatocellular carcinoma. Hepatology 49(5), 1492–1502 (2009).
   PubMedGoogle Scholar
• Song S, Zhang K, You H et al. Significant anti-tumour activity of adoptively transferred T cells elicited by intratumoral dendritic cell vaccine injection through enhancing the ratio of CD8+ T cell/regulatory T cells in tumour. Clin. Exp. Immunol. 162(1), 75–83 (2010).
   PubMed Web of Science ®Google Scholar
• Milich DR, McLachlan A, Stahl S et al. Comparative immunogenicity of hepatitis B virus core and E antigens. J. Immunol. 141(10), 3617–3624 (1988).
   PubMed Web of Science ®Google Scholar
• Fehr T, Skrastina D, Pumpens P, Zinkernagel RM. T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles. Proc. Natl Acad. Sci. USA 95(16), 9477–9481 (1998).
   PubMed Web of Science ®Google Scholar
• Vanlandschoot P, Van Houtte F, Serruys B, Leroux-Roels G. The arginine-rich carboxy-terminal domain of the hepatitis B virus core protein mediates attachment of nucleocapsids to cell-surface-expressed heparan sulfate. J. Gen. Virol. 86(Pt 1), 75–84 (2005).
   PubMed Web of Science ®Google Scholar
• Vanlandschoot P, Van Houtte F, Ulrichts P, Tavernier J, Leroux-Roels G. Immunostimulatory potential of hepatitis B nucleocapsid preparations: lipopolysaccharide contamination should not be overlooked. J. Gen. Virol. 86(Pt 2), 323–331 (2005).
   PubMed Web of Science ®Google Scholar
• Vanlandschoot P, Van Houtte F, Serruys B, Leroux-Roels G. Contamination of a recombinant hepatitis B virus nucleocapsid preparation with a human B-cell activator. J. Virol. 81(5), 2535–2536 (2007).
   PubMed Web of Science ®Google Scholar
• Crompton PD, Pierce SK, Miller LH. Advances and challenges in malaria vaccine development. J. Clin. Invest. 120(12), 4168–4178 (2010).
   PubMed Web of Science ®Google Scholar
• Nussenzweig RS, Vanderberg J, Most H, Orton C. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. Nature 216(5111), 160–162 (1967).
   PubMed Web of Science ®Google Scholar
• Clyde DF, McCarthy VC, Miller RM, Hornick RB. Specificity of protection of man immunized against sporozoite-induced falciparum malaria. Am. J. Med. Sci. 266(6), 398–403 (1973).
   PubMed Web of Science ®Google Scholar
• Rieckmann KH, Beaudoin RL, Cassells JS, Sell KW. Use of attenuated sporozoites in the immunization of human volunteers against falciparum malaria. Bull. World Health Organ. 57(Suppl. 1), 261–265 (1979).
   PubMedGoogle Scholar
• Nussenzweig V, Nussenzweig RS. Development of a sporozoite malaria vaccine. Am. J. Trop. Med. Hyg. 35(4), 678–688 (1986).
   PubMed Web of Science ®Google Scholar
• Ballou WR, Hoffman SL, Sherwood JA et al. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet 1(8545), 1277–1281 (1987).
   PubMed Web of Science ®Google Scholar
• Herrington DA, Clyde DF, Losonsky G et al. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature 328(6127), 257–259 (1987).
   PubMed Web of Science ®Google Scholar
• Schödel F, Wirtz R, Peterson D et al. Immunity to malaria elicited by hybrid hepatitis B virus core particles carrying circumsporozoite protein epitopes. J. Exp. Med. 180(3), 1037–1046 (1994).
   PubMed Web of Science ®Google Scholar
• Sällberg M, Hughes J, Jones J, Phillips TR, Milich DR. A malaria vaccine candidate based on a hepatitis B virus core platform. Intervirology 45(4-6), 350–361 (2002).
   PubMedGoogle Scholar
• Milich DR, Hughes J, Jones J, Sällberg M, Phillips TR. Conversion of poorly immunogenic malaria repeat sequences into a highly immunogenic vaccine candidate. Vaccine 20(5-6), 771–788 (2001).
   PubMed Web of Science ®Google Scholar
• Birkett A, Lyons K, Schmidt A et al. A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts. Infect. Immun. 70(12), 6860–6870 (2002).
   PubMed Web of Science ®Google Scholar
• Oliveira GA, Wetzel K, Calvo-Calle JM et al. Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial. Infect. Immun. 73(6), 3587–3597 (2005).
   PubMed Web of Science ®Google Scholar
• Nardin EH, Oliveira GA, Calvo-Calle JM et al. Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes. Infect. Immun. 72(11), 6519–6527 (2004).
   PubMed Web of Science ®Google Scholar
• Walther M, Dunachie S, Keating S et al. Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720. Vaccine 23(7), 857–864 (2005).
   PubMed Web of Science ®Google Scholar
• Gregson AL, Oliveira G, Othoro C et al. Phase I trial of an alhydrogel adjuvanted hepatitis B core virus-like particle containing epitopes of Plasmodium falciparum circumsporozoite protein. PLoS One 3(2), e1556 (2008).
   PubMed Web of Science ®Google Scholar
• Good MF, Pombo D, Quakyi IA et al. Human T-cell recognition of the circumsporozoite protein of Plasmodium falciparum: immunodominant T-cell domains map to the polymorphic regions of the molecule. Proc. Natl Acad. Sci. USA 85(4), 1199–1203 (1988).
   PubMed Web of Science ®Google Scholar
• Rutgers T, Gordon D, Gathoye AM et al. Hepatitis B surface antigen as carrier matrix for the repetitive epitope of the circumsporozoite protein of Plasmodium falciparum. Nature Biotechnology 6(9), 1065–1070 (1988).
   Google Scholar
• Gordon DM, McGovern TW, Krzych U et al. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J. Infect. Dis. 171(6), 1576–1585 (1995).
   PubMed Web of Science ®Google Scholar
• Garçon N, Chomez P, Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev. Vaccines 6(5), 723–739 (2007).
   PubMed Web of Science ®Google Scholar
• Cohen J, Nussenzweig V, Nussenzweig R, Vekemans J, Leach A. From the circumsporozoite protein to the RTS, S/AS candidate vaccine. Hum. Vaccin. 6(1), 90–96 (2010).
   PubMed Web of Science ®Google Scholar
• Schwenk RJ, Richie TL. Protective immunity to pre-erythrocytic stage malaria. Trends Parasitol. 27(7), 306–314 (2011).
   PubMed Web of Science ®Google Scholar
• Lamb RA, Choppin PW. Identification of a second protein (M2) encoded by RNA segment 7 of influenza virus. Virology 112(2), 729–737 (1981).
   PubMed Web of Science ®Google Scholar
• Pinto LH, Holsinger LJ, Lamb RA. Influenza virus M2 protein has ion channel activity. Cell 69(3), 517–528 (1992).
   PubMed Web of Science ®Google Scholar
• Takeda M, Pekosz A, Shuck K, Pinto LH, Lamb RA. Influenza a virus M2 ion channel activity is essential for efficient replication in tissue culture. J. Virol. 76(3), 1391–1399 (2002).
   PubMedGoogle Scholar
• Iwatsuki-Horimoto K, Horimoto T, Noda T et al. The cytoplasmic tail of the influenza A virus M2 protein plays a role in viral assembly. J. Virol. 80(11), 5233–5240 (2006).
   PubMedGoogle Scholar
• Chen BJ, Leser GP, Jackson D, Lamb RA. The influenza virus M2 protein cytoplasmic tail interacts with the M1 protein and influences virus assembly at the site of virus budding. J. Virol. 82(20), 10059–10070 (2008).
   PubMed Web of Science ®Google Scholar
• Gannagé M, Dormann D, Albrecht R et al. Matrix protein 2 of influenza A virus blocks autophagosome fusion with lysosomes. Cell Host Microbe 6(4), 367–380 (2009).
   PubMed Web of Science ®Google Scholar
• Rossman JS, Jing X, Leser GP, Balannik V, Pinto LH, Lamb RA. Influenza virus m2 ion channel protein is necessary for filamentous virion formation. J. Virol. 84(10), 5078–5088 (2010).
   PubMed Web of Science ®Google Scholar
• Rossman JS, Jing X, Leser GP, Lamb RA. Influenza virus M2 protein mediates ESCRT-independent membrane scission. Cell 142(6), 902–913 (2010).
   PubMedGoogle Scholar
• Guan Z, Liu D, Mi S et al. Interaction of Hsp40 with influenza virus M2 protein: implications for PKR signaling pathway. Protein Cell 1(10), 944–955 (2010).
   PubMedGoogle Scholar
• Roose K, Fiers W, Saelens X. Pandemic preparedness: toward a universal influenza vaccine. Drug News Perspect. 22(2), 80–92 (2009).
   PubMedGoogle Scholar
• Roose K, Schotsaert M, Bakkouri KE, Schepens B, Fiers W, Saelens X. Cutting edge approaches toward novel and cross-protective influenza vaccines. In: Development of Novel Vaccines. von Gabain A, Klade C (Eds). Springer, NY, USA, 205–232 (2012).
   Google Scholar
• Saelens X. The influenza matrix protein 2 as a vaccine target. Future Virology 3(2), 167–178 (2008).
   Google Scholar
• Schotsaert M, De Filette M, Fiers W, Saelens X. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev. Vaccines 8(4), 499–508 (2009).
   PubMed Web of Science ®Google Scholar
• Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med. 5(10), 1157–1163 (1999).
   PubMed Web of Science ®Google Scholar
• De Filette M, Ramne A, Birkett A et al. The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection. Vaccine 24(5), 544–551 (2006).
   PubMed Web of Science ®Google Scholar
• De Filette M, Martens W, Smet A et al. Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies. Vaccine 26(51), 6503–6507 (2008).
   PubMed Web of Science ®Google Scholar
• Fiers W, De Filette M, El Bakkouri K et al. M2e-based universal influenza A vaccine. Vaccine 27(45), 6280–6283 (2009).
   PubMed Web of Science ®Google Scholar
• Zhang GG, Li DX, Zhang HH, Zeng YM, Chen L. Enhancement of mucosal immune response against the M2eHBc+ antigen in mice with the fusion expression products of LTB and M2eHBc+ through mucosal immunization route. Vet. Res. Commun. 33(7), 735–747 (2009).
   PubMedGoogle Scholar
• Ameiss K, Ashraf S, Kong W et al. Delivery of woodchuck hepatitis virus-like particle presented influenza M2e by recombinant attenuated Salmonella displaying a delayed lysis phenotype. Vaccine 28(41), 6704–6713 (2010).
   PubMed Web of Science ®Google Scholar
• Nemchinov LG, Natilla A. Transient expression of the ectodomain of matrix protein 2 (M2e) of avian influenza A virus in plants. Protein Expr. Purif. 56(2), 153–159 (2007).
   PubMedGoogle Scholar
• Denis J, Acosta-Ramirez E, Zhao Y et al. Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Vaccine 26(27–28), 3395–3403 (2008).
   PubMed Web of Science ®Google Scholar
• Bessa J, Schmitz N, Hinton HJ, Schwarz K, Jegerlehner A, Bachmann MF. Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design. Eur. J. Immunol. 38(1), 114–126 (2008).
   PubMed Web of Science ®Google Scholar
• Tissot AC, Renhofa R, Schmitz N et al. Versatile virus-like particle carrier for epitope based vaccines. PLoS One 5(3), e9809 (2010).
   PubMed Web of Science ®Google Scholar
• Michel ML, Tiollais P. Hepatitis B vaccines: protective efficacy and therapeutic potential. Pathol. Biol. 58(4), 288–295 (2010).
   PubMed Web of Science ®Google Scholar
• Neurath AR, Seto B, Strick N. Antibodies to synthetic peptides from the preS1 region of the hepatitis B virus (HBV) envelope (env) protein are virus-neutralizing and protective. Vaccine 7(3), 234–236 (1989).
   PubMed Web of Science ®Google Scholar
• Milich DR, McLachlan A, Chisari FV, Kent SB, Thorton GB. Immune response to the pre-S (1) region of the hepatitis B surface antigen (HBsAg): a pre-S (1)-specific T cell response can bypass nonresponsiveness to the pre-S (2) and S regions of HBsAg. J. Immunol. 137(1), 315 (1986).
   PubMed Web of Science ®Google Scholar
• Chen X, Li M, Le X, Ma W, Zhou B. Recombinant hepatitis B core antigen carrying preS1 epitopes induce immune response against chronic HBV infection. Vaccine 22(3–4), 439–446 (2004).
   PubMedGoogle Scholar
• Yue Q, Hu X, Yin W et al. Immune responses to recombinant Mycobacterium smegmatis expressing fused core protein and preS1 peptide of hepatitis B virus in mice. J. Virol. Methods 141(1), 41–48 (2007).
   PubMedGoogle Scholar
• Yang HJ, Chen M, Cheng T et al. Expression and immunoactivity of chimeric particulate antigens of receptor binding site-core antigen of hepatitis B virus. World J. Gastroenterol. 11(4), 492–497 (2005).
   PubMedGoogle Scholar
• Skrastina D, Bulavaite A, Sominskaya I et al. High immunogenicity of a hydrophilic component of the hepatitis B virus preS1 sequence exposed on the surface of three virus-like particle carriers. Vaccine 26(16), 1972–1981 (2008).
   PubMed Web of Science ®Google Scholar
• Bremer CM, Sominskaya I, Skrastina D et al. N-terminal myristoylation-dependent masking of neutralizing epitopes in the preS1 attachment site of hepatitis B virus. J. Hepatol. 55(1), 29–37 (2011).
   PubMedGoogle Scholar
• Engelke M, Mills K, Seitz S et al. Characterization of a hepatitis B and hepatitis delta virus receptor binding site. Hepatology 43(4), 750–760 (2006).
   PubMed Web of Science ®Google Scholar
• Gripon P, Le Seyec J, Rumin S, Guguen-Guillouzo C. Myristylation of the hepatitis B virus large surface protein is essential for viral infectivity. Virology 213(2), 292–299 (1995).
   PubMed Web of Science ®Google Scholar
• Tan YJ. Hepatitis B virus infection and the risk of hepatocellular carcinoma. World J. Gastroenterol. 17(44), 4853–4857 (2011).
   PubMed Web of Science ®Google Scholar
• Kwon H, Lok AS. Does antiviral therapy prevent hepatocellular carcinoma? Antivir. Ther. (Lond.) 16(6), 787–795 (2011).
   PubMed Web of Science ®Google Scholar
• Shen YC, Hsu C, Cheng CC, Hu FC, Cheng AL. A critical evaluation of the preventive effect of antiviral therapy on the development of hepatocellular carcinoma in patients with chronic hepatitis C or B: a novel approach by using meta-regression. Oncology 82(5), 275–289 (2012).
   PubMedGoogle Scholar
• Ng SA, Lee C. Hepatitis B virus X gene and hepatocarcinogenesis. J. Gastroenterol. 46(8), 974–990 (2011).
   PubMed Web of Science ®Google Scholar
• Herzenberg LA, Tokuhisa T, Parks DR, Herzenberg LA. Epitope-specific regulation. II. A bistable, Igh-restricted regulatory mechanism central to immunologic memory. J. Exp. Med. 155(6), 1741–1753 (1982).
   PubMed Web of Science ®Google Scholar
• Geldmacher A, Skrastina D, Borisova G et al. A hantavirus nucleocapsid protein segment exposed on hepatitis B virus core particles is highly immunogenic in mice when applied without adjuvants or in the presence of pre-existing anti-core antibodies. Vaccine 23(30), 3973–3983 (2005).
   PubMed Web of Science ®Google Scholar
• Belnap DM, Watts NR, Conway JF et al. Diversity of core antigen epitopes of hepatitis B virus. Proc. Natl Acad. Sci. USA 100(19), 10884–10889 (2003).
   PubMedGoogle Scholar
• De Filette M, Fiers W, Martens W et al. Improved design and intranasal delivery of an M2e-based human influenza A vaccine. Vaccine 24(44–46), 6597–6601 (2006).
   PubMed Web of Science ®Google Scholar
• Baumert TF, Thimme R, von Weizsäcker F. Pathogenesis of hepatitis B virus infection. World J. Gastroenterol. 13(1), 82–90 (2007).
   PubMedGoogle Scholar
• Ferrari C, Penna A, Bertoletti A et al. Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. J. Immunol. 145(10), 3442–3449 (1990).
   PubMed Web of Science ®Google Scholar
• Billaud JN, Peterson D, Schödel F et al. Comparative antigenicity and immunogenicity of hepadnavirus core proteins. J. Virol. 79(21), 13641–13655 (2005).
   PubMed Web of Science ®Google Scholar
• Billaud JN, Peterson D, Lee BO et al. Advantages to the use of rodent hepadnavirus core proteins as vaccine platforms. Vaccine 25(9), 1593–1606 (2007).
   PubMed Web of Science ®Google Scholar
• Riedl P, Stober D, Oehninger C, Melber K, Reimann J, Schirmbeck R. Priming Th1 immunity to viral core particles is facilitated by trace amounts of RNA bound to its arginine-rich domain. J. Immunol. 168(10), 4951–4959 (2002).
   PubMed Web of Science ®Google Scholar
• Arora U, Tyagi P, Swaminathan S, Khanna N. Chimeric Hepatitis B core antigen virus-like particles displaying the envelope domain III of dengue virus type 2. J. Nanobiotechnology 10, 30 (2012).
   PubMed Web of Science ®Google Scholar
• Sun C, Ding FX, Wang F et al. Screen of multifunctional monoclonal antibodies against hepatitis B core virus-like particles. Microbiol. Immunol. 53(6), 340–348 (2009).
   PubMedGoogle Scholar
• Malik IR, Chen A, Brass A et al. A bi-functional hepatitis B virus core antigen (HBcAg) chimera activates HBcAg-specific T cells and preS1-specific antibodies. Scand. J. Infect. Dis. 44(1), 55–59 (2012).
   PubMed Web of Science ®Google Scholar
• Huang Y, Liang W, Wang Y et al. Immunogenicity of the epitope of the foot-and-mouth disease virus fused with a hepatitis B core protein as expressed in transgenic tobacco. Viral Immunol. 18(4), 668–677 (2005).
   PubMed Web of Science ®Google Scholar
• Zhang YL, Guo YJ, Wang KY et al. Enhanced immunogenicity of modified hepatitis B virus core particle fused with multiepitopes of foot-and-mouth disease virus. Scand. J. Immunol. 65(4), 320–328 (2007).
   PubMedGoogle Scholar
• Boulter NR, Glass EJ, Knight PA, Bell-Sakyi L, Brown CG, Hall R. Theileria annulata sporozoite antigen fused to hepatitis B core antigen used in a vaccination trial. Vaccine 13(13), 1152–1160 (1995).
   PubMedGoogle Scholar
• Ulrich R, Borisova GP, Gren E et al. Immunogenicity of recombinant core particles of hepatitis B virus containing epitopes of human immunodeficiency virus 1 core antigen. Arch. Virol. 126(1–4), 321–328 (1992).
   PubMedGoogle Scholar
• Stahl SJ, Murray K. Immunogenicity of peptide fusions to hepatitis B virus core antigen. Proc. Natl Acad. Sci. USA 86(16), 6283–6287 (1989).
   PubMed Web of Science ®Google Scholar
• von Brunn A, Brand M, Reichhuber C, Morys-Wortmann C, Deinhardt F, Schödel F. Principal neutralizing domain of HIV-1 is highly immunogenic when expressed on the surface of hepatitis B core particles. Vaccine 11(8), 817–824 (1993).
   PubMed Web of Science ®Google Scholar
• Takeda S, Shiosaki K, Kaneda Y et al. Hemagglutinating virus of Japan protein is efficient for induction of CD4+ T-cell response by a hepatitis B core particle-based HIV vaccine. Clin. Immunol. 112(1), 92–105 (2004).
   PubMedGoogle Scholar
• Oldenburg DJ, Kumar RA, Bendich AJ. The amount and integrity of mtDNA in maize decline with development. Planta doi:10.1007/s00425-012-1802-z (2012) (Epub ahead of print).
   PubMedGoogle Scholar
• Geldmacher A, Skrastina D, Petrovskis I et al. An amino-terminal segment of hantavirus nucleocapsid protein presented on hepatitis B virus core particles induces a strong and highly cross-reactive antibody response in mice. Virology 323(1), 108–119 (2004).
   PubMed Web of Science ®Google Scholar
• Pumpens P, Razanskas R, Pushko P et al. Evaluation of HBs, HBc, and frCP virus-like particles for expression of human papillomavirus 16 E7 oncoprotein epitopes. Intervirology 45(1), 24–32 (2002).
   PubMed Web of Science ®Google Scholar
• Chen JY, Li F. Development of hepatitis C virus vaccine using hepatitis B core antigen as immuno-carrier. World J. Gastroenterol. 12(48), 7774–7778 (2006).
   PubMedGoogle Scholar
• Sominskaya I, Skrastina D, Dislers A et al. Construction and immunological evaluation of multivalent hepatitis B virus (HBV) core virus-like particles carrying HBV and HCV epitopes. Clin. Vaccine Immunol. 17(6), 1027–1033 (2010).
   PubMed Web of Science ®Google Scholar